Immunogenicity and Tolerability to Human Papillomavirus-like Particle Vaccine in Girls and Young Women with Inflammatory Bowel Disease

被引:63
|
作者
Jacobson, Denise L. [1 ]
Bousvaros, Athos [2 ]
Ashworth, Lori [2 ]
Carey, Rebecca [3 ]
Shrier, Lydia A. [4 ]
Burchett, Sandra K. [5 ]
Renna, Harmony [3 ]
Lu, Ying [6 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA
[2] Boston Childrens Hosp, Ctr Inflammatory Bowel Dis, Div Gastroenterol Hepatol & Nutr, Boston, MA USA
[3] Maine Pediat Grp, Portland, ME USA
[4] Boston Childrens Hosp, Div Adolescent Young Adult Med, Boston, MA USA
[5] Boston Childrens Hosp, Div Infect Dis, Boston, MA USA
[6] Cohen Childrens Med Ctr, Div Pediat Gastroenterol & Nutr, New Hyde Pk, NY USA
基金
美国国家卫生研究院;
关键词
inflammatory bowel disease; immunosuppressive therapy; human papillomavirus vaccine; immunogenicity; girls and young women; IMMUNE-RESPONSE; SUSCEPTIBILITY LOCI; PEDIATRIC-PATIENTS; INFLUENZA VACCINE; CROHNS-DISEASE; ACTIVITY INDEX; HPV INFECTION; CHILDREN; SAFETY; ASSOCIATION;
D O I
10.1097/MIB.0b013e318281341b
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background:Female patients receiving immunosuppressive therapy may be at increased risk for human papillomavirus (HPV) infection and cervical neoplasia.Methods:We administered the 3-dose HPV vaccine Gardasil to 37 females aged 9 to 26 years with inflammatory bowel disease (IBD) prescribed immunosuppressive therapy (prospective cohort). Geometric mean titers (GMT) in milli-Merck (mMu/mL) units were determined before dose 1 and 1 month after dose 3 by competitive Luminex immunoassay (cLIA) and qualitatively compared with healthy females of similar age from Merck's database. Side effects and adverse events were evaluated. Concurrently, in 15 similar patients with inflammatory bowel disease previously vaccinated by their primary care provider, we assessed antibody titers by competitive Luminex immunoassay and total immunoglobulin G LIA after dose 3 of vaccine (range, 0.5-27 months).Results:Mean age of prospective patients was 15 years with 51% on anti-tumor necrosis factor therapy and 49% on immunomodulators: 33 of 37 completed all 3 doses. Seropositivity after dose 3 was 100% for types 6, 11 and 16 and 96% for type 18. Geometric mean titers for HPV-6, HPV-11, HPV-16 and HPV-18 was 1080, 1682, 3975 and 858, respectively and did not qualitatively differ from healthy females. No serious adverse events were attributable to the vaccine. In the previously vaccinated cohort, seropositivity was 100% for types 6, 11, and 16, and 40% for type 18 by competitive Luminex immunoassay (93% for HPV-18 by immunoglobulin G LIA). Titers decreased with time since dose 3.Conclusions:In this small study of patients with inflammatory bowel disease prescribed immunosuppressive therapy, Gardasil was immunogenic and there were no clinically significant vaccine-associated adverse events.
引用
收藏
页码:1441 / 1449
页数:9
相关论文
共 50 条
  • [11] Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia
    Einstein, Mark H.
    Studentsov, Yevgeniy Y.
    Ho, Gloria Y. F.
    Fazzari, Melissa
    Marks, Morgan
    Kadish, Anna S.
    Goldberg, Gary L.
    Runowicz, Carolyn D.
    Burk, Robert D.
    INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (01) : 55 - 59
  • [12] IMMUNOGENICITY OF QUADRIVALENT INFLUENZA VACCINE FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Sakata, Yasuhisa
    Shirai, Shimpei
    Hara, Megumi
    Tsuruoka, Nanae
    Shimoda, Ryo
    Fujimoto, Kazuma
    GUT, 2018, 67 : A42 - A42
  • [13] IMMUNOGENICITY OF HEPATITIS A VACCINE IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Radzikowski, A.
    Banaszkiewicz, A.
    Lazowska-Przeorek, I.
    Grzybowska-Chlebowczyk, U.
    Wos, H.
    Pytrus, T.
    Iwanczak, B.
    Kowalska-Duplaga, K.
    Fyderek, K.
    Gawronska, A.
    Karolewska-Bochenek, K.
    Kotowska, M.
    Albrecht, P.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2010, 50 : E97 - E97
  • [14] Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis
    Esposito, Susanna
    Corona, Fabrizia
    Barzon, Luisa
    Cuoco, Federica
    Squarzon, Laura
    Marcati, Giorgia
    Torcoletti, Marta
    Gambino, Monia
    Palu, Giorgio
    Principi, Nicola
    EXPERT REVIEW OF VACCINES, 2014, 13 (11) : 1387 - 1393
  • [15] Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant
    Oh, YK
    Sohn, T
    Park, JS
    Kang, MJ
    Choi, HG
    Kim, JA
    Kim, WK
    Ko, JJ
    Kim, CK
    VIROLOGY, 2004, 328 (02) : 266 - 273
  • [16] Papillomavirus-like particle Aβ vaccine induces strong antibody response in APP/PS1 transgenic mice
    Zamora, ED
    Troncoso, JC
    Borchelt, DR
    Handisurya, A
    Kirnbauer, R
    ANNALS OF NEUROLOGY, 2003, 54 : S29 - S29
  • [17] Attitudes about human papillomavirus vaccine in young women
    Kahn, JA
    Rosenthal, SL
    Hamann, T
    Bernstein, DI
    INTERNATIONAL JOURNAL OF STD & AIDS, 2003, 14 (05) : 300 - 306
  • [18] Safety and Immunogenicity of the Nonavalent Human Papillomavirus Vaccine in Women Living with HIV
    Hidalgo-Tenorio, Carmen
    Moya, Raquel
    Omar, Mohamed
    Munoz, Leopoldo
    SamPedro, Antonio
    Lopez-Hidalgo, Javier
    Garcia-Vallecillos, Coral
    Gomez-Ronquillo, Patricia
    VACCINES, 2024, 12 (08)
  • [19] A Preclinical Immunogenicity Study of the Recombinant Human Papillomavirus Nine-Valent Virus-like Particle Vaccine
    Xu, Dan
    Li, Jia-Dai
    An, Jiao
    Ma, Xin-Xing
    Wang, Xiao-Liang
    Zhou, Zheng
    Liu, Hai-Ping
    Diao, Mei-Jun
    Jiang, Yuan-Xiang
    Zhou, Ling-Yun
    Tong, Xin
    Zhou, Chen-Liang
    VACCINES, 2024, 12 (12)
  • [20] Prevention of human papillomavirus infection: Provisional recommendations for immunization of girls and women with quadrivalent human papillomavirus vaccine
    Bocchini, Joseph A., Jr.
    Baltimore, Robert S.
    Bernstein, Henry R.
    Bradley, John S.
    Brady, Michael T.
    Dennehy, Penelope H.
    Fisher, Margaret C.
    Frenck, Robert W., Jr.
    Kimberlin, David W.
    Long, Sarah S.
    McMillan, Julia A.
    Rubin, Lorry G.
    PEDIATRICS, 2007, 120 (03) : 666 - 668